Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Toxic epidermal necrolysis induced by lamotrigine treatment in a child

  • Yi, Youngsuk (Department of Pediatrics, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine) ;
  • Lee, Jeong Ho (Department of Pediatrics, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine) ;
  • Suh, Eun Sook (Department of Pediatrics, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine)
  • Received : 2013.01.11
  • Accepted : 2013.07.19
  • Published : 2014.03.15
Download PDF
⟨ Previous Next ⟩

Abstract

Toxic epidermal necrolysis is an unpredictable and severe adverse drug reaction. In toxic epidermal necrolysis, epidermal damage appears to result from keratinocyte apoptosis. This condition is triggered by many factors, principally drugs such as antiepileptic medications, antibiotics (particularly sulfonamide), nonsteroidal anti-inflammatory drugs, allopurinol, and nevirapine. Lamotrigine has been reported potentially cause serious cutaneous reactions, and concomitant use of valproic acid with lamotrigine significantly increases this risk. We describe a case of an 11-year-old girl with tic and major depressive disorders who developed toxic epidermal necrolysis after treatment with lamotrigine, and who was diagnosed both clinically and pathologically. Children are more susceptible to lamotrigine-induced rash than adults, and risk of serious rash can be lessened by strict adherence to dosing guidelines. Unfortunately, in our case, the patient was administered a higher dose than the required regimen. Therefore, clinicians should strictly adhere to the dose regimen when using lamotrigine, especially in children.

Keywords

References

  1. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol 2007;56:181-200. https://doi.org/10.1016/j.jaad.2006.04.048
  2. Downey A, Jackson C, Harun N, Cooper A. Toxic epidermal necrolysis: review of pathogenesis and management. J Am Acad Dermatol 2012;66:995-1003. https://doi.org/10.1016/j.jaad.2011.09.029
  3. Harr T, French LE. Stevens-Johnson syndrome and toxic epidermal necrolysis. Chem Immunol Allergy 2012;97:149-66. https://doi.org/10.1159/000335627
  4. Chang CC, Shiah IS, Chang HA, Huang SY. Toxic epidermal necrolysis with combination lamotrigine and valproate in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:147-50. https://doi.org/10.1016/j.pnpbp.2005.08.025
  5. Hirsch LJ, Weintraub DB, Buchsbaum R, Spencer HT, Straka T, Hager M, et al. Predictors of Lamotrigine-associated rash. Epilepsia 2006;47:318-22. https://doi.org/10.1111/j.1528-1167.2006.00423.x
  6. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010;5:39. https://doi.org/10.1186/1750-1172-5-39
  7. Kim DW, Jung DE, Koo JW. Steroid and enalapril therapy-possible cause of toxic epidermal necrolysis. Korean J Pediatr 2006;49:332-6. https://doi.org/10.3345/kjp.2006.49.3.332
  8. Joseph G. Morelli. Vesiculobullous disorders. In: Kliegman RM, Stanton BF, St. Geme JW III, Schor NF, Behrman RE, editors. Nelsn textbook of pediatrics. 19th ed. Philadelphia: Elsevier Saunders, 2011:2243.
  9. Abood GJ, Nickoloff BJ, Gamelli RL. Treatment strategies in toxic epidermal necrolysis syndrome: where are we at? J Burn Care Res 2008;29:269-76. https://doi.org/10.1097/BCR.0b013e31815f3658
  10. Gerull R, Nelle M, Schaible T. Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review. Crit Care Med 2011;39:1521-32. https://doi.org/10.1097/CCM.0b013e31821201ed
  11. Warnock JK, Morris DW. Adverse cutaneous reactions to mood stabilizers. Am J Clin Dermatol 2003;4:21-30. https://doi.org/10.2165/00128071-200304010-00003
  12. Kim KJ, Lee DP, Suh HS, Lee MW, Choi JH, Moon KC, et al. Toxic epidermal necrolysis: analysis of clinical course and SCORTENbased comparison of mortality rate and treatment modalities in Korean patients. Acta Derm Venereol 2005;85:497-502.
  13. Lissia M, Mulas P, Bulla A, Rubino C. Toxic epidermal necrolysis (Lyell's disease). Burns 2010;36:152-63. https://doi.org/10.1016/j.burns.2009.06.213
  14. Ruetter A, Luger TA. Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view. Am J Clin Dermatol 2004;5:153-60. https://doi.org/10.2165/00128071-200405030-00003
  15. Li LM, Russo M, O'Donoghue MF, Duncan JS, Sander JW. Allergic skin rash with lamotrigine and concomitant valproate therapy: evidence for an increased risk. Arq Neuropsiquiatr 1996;54:47-9. https://doi.org/10.1590/S0004-282X1996000100008
  16. Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998;39 Suppl 7:S22-6. https://doi.org/10.1111/j.1528-1157.1998.tb01681.x
  17. Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999;40:985-91. https://doi.org/10.1111/j.1528-1157.1999.tb00807.x

Cited by

  1. Evidence-Based Pharmacotherapy of Epilepsy vol.2, pp.2, 2014, https://doi.org/10.5812/archneurosci.18468
  2. Multidrug-related leukocytoclastic vasculitis raising suspicion of sexual homicide-things are not always what they seem vol.130, pp.1, 2014, https://doi.org/10.1007/s00414-015-1202-6
  3. Successful Combination Therapy Including Plasma Exchange for Severe Toxic Epidermal Necrolysis vol.17, pp.3, 2014, https://doi.org/10.14442/jgfm.17.3_232